Systems announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy trial ...

At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively.At 12 months, the WRAPSODY CIE achieved 70.1% and 58.1% target ...